Knee osteoarthritis
Conditions
Interventions
Experimental group:Mesenchymal stem cells and sodium hyaluronate were injected into the knee cavity
Control group:Sodium hyaluronate was injected into the knee cavity
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) patients with primary knee osteoarthritis aged 45-70 years; (2) Patients who had received NSAIDS and physical therapy regularly for 6 weeks and had no improvement in knee pain VAS score or knee function KSS score; Or regular non-steroidal anti-inflammatory drugs and physical therapy for more than 6 weeks within a year, knee pain VAS score of more than 3 times in a year more than 4 points; (3) The patient met the X-ray KL classification of both knee joints = level 2, and the classification of both knee joints was consistent; (4) The difference in VAS scores for pain of both knees was no more than 2 points; (5) Coagulation function: D-dimer quantification (DD) < 255 ng/mL, plasma prothrombin time (PT) 8.8-13.4 S, prothrombin activity (PTA) 70-160%, thrombin time (TT) 11.0-17.8 S, activated partial thrombin time (APTT) 23.3-38.1 S; (6) Erythrocyte sedimentation rate 0-20 mm/h, CRP< 0.8 mg/dl; (7) Blood routine: red blood cells 3.8-5.8×10^12 /L, hemoglobin 115-175 g/L, white blood cells 3.5-9.5×10^9 /L, platelet count 125-350×10^9 /L, neutrophil percentage 40-75%.
Exclusion criteria
Exclusion criteria: (1) Patients who had received intra-articular injection therapy within 3 months; (2) KL grade of knee imaging X-rays > Grade 2; (3) Had a knee infection within 12 weeks, or had a knee injury within 12 weeks; (4) Rheumatoid arthritis and other autoimmune arthritis; (5) Patients with gastrointestinal ulcer, coronary heart disease and other contraindications to use NSAIDS; (6) Patients with tumor, diabetes, blood system diseases, local skin diseases and systemic allergies; (7) Patients with immunodeficiency or who have received immunosuppressive therapy within 12 weeks; (8) Received anticoagulation or anticoagulation therapy within 4 weeks; (9) Patients with other serious diseases who could not cooperate with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Short-term security;Clinical score;Image score; | — |
Countries
China
Contacts
Public ContactMa Jie; Chen Min; Xue Qingyun
Beijing Hospital
Outcome results
None listed